insights_auto
Kāpēc uzņēmuma OPHLY akciju cena ir pieaugusi 5,91%?
Atklājiet vairāk iespējuchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,92 $
arrow_upward
+5,91%(+0,28) 1 d.
15. okt., 16:00:00 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: OPHLY…
Atvērt
4,96 $
Augsta
4,96 $
Zema
4,90 $
Tirgus kapitalizācija
1,20 trilj.
Vid. apjoms
61,54 tūkst.
Apjoms
68,37 tūkst.
Augstākā 52 ned.
5,75 $
Zemākā 52 ned.
3,82 $
Beta
0,21
Apgrozībā esošās akcijas
1,50 mljrd.
Darbinieku skaits
4 tūkst.
Atvērt
4,96 $
Augsta
4,96 $
Zema
4,90 $
Tirgus kapitalizācija
1,20 trilj.
Vid. apjoms
61,54 tūkst.
Apjoms
68,37 tūkst.
Augstākā 52 ned.
5,75 $
Zemākā 52 ned.
3,82 $
Beta
0,21
Apgrozībā esošās akcijas
1,50 mljrd.
Darbinieku skaits
4 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Stock Titan
·
pirms 15 minūtēm
32 new hires get awards tied to 57,853 shares, but vesting depends on continued employment.
American Ag Network
·
pirms 9 minūtēm
NYSE Owner Challenges CME in Livestock Futures Market
Kursiv Media
·
pirms 9 minūtēm
Kazakhstani scooter-sharing operator JET eyes Nasdaq or LSE IPO after 2028
Yahoo Finance
·
pirms 20 minūtēm
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
Profils
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Par “Ono Pharmaceutical ADR Representing 1/3rd Ord Shs”
ĢenerāldirektorsGyo Sagara | Gyo Sagara
Darbinieki4,21 tūkst.
Dibināšanas datums1717
Galvenais birojsOsaka, Osakas prefektūra, Japāna
Sektors-
Tīmekļa vietneono-pharma.com